{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T18:11:34Z","timestamp":1759947094104,"version":"build-2065373602"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020627","name":"Kerman Neuroscience Research Center, Kerman University of Medical Sciences","doi-asserted-by":"publisher","award":["01-12"],"award-info":[{"award-number":["01-12"]}],"id":[{"id":"10.13039\/501100020627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease globally, characterized by insulin resistance, hypertension, and obesity. Adipokines such as resistin and visfatin play significant roles in glucose homeostasis and lipid metabolism. Polypills are utilized to improve cardiovascular disease (CVD) risk factors. The present observational study was nested within the PolyIran-Liver randomized controlled trial, which primarily assessed clinical outcomes in NAFLD patients. This study aimed to evaluate the effects of prolonged polypill consumption (five years) on circulating levels of resistin and visfatin as secondary outcomes in men with NAFLD. Participants from the PolyIran-Liver trial were included, comprising 41 patients in the control group and 40 patients in the polypill group, all of whom were men. The polypill regimen included aspirin, hydrochlorothiazide, atorvastatin, and valsartan. Treatment with the polypill resulted in a significant reduction in visfatin levels (2.27\u2009\u00b1\u20090.83\u2009ng\/ml vs. 2.10\u2009\u00b1\u20090.71\u2009ng\/ml, AdjP\u2009=\u20090.041), but no significant changes in resistin levels were observed within the polypill group (19.54\u2009\u00b1\u20094.11\u2009ng\/ml vs. 19.11\u2009\u00b1\u20093.08\u2009ng\/ml, AdjP\u2009=\u20090.396). The reduction in visfatin levels from baseline was significantly associated with changes in resistin levels and fasting blood glucose (FBG) (P\u2009&lt;\u20090.05). Additionally, polypill intervention improved alanine aminotransferase (ALT) levels, lipid profiles, and systolic blood pressure in patients with NAFLD (P\u2009&lt;\u20090.05). Our findings suggest that daily intake of the polypill can lead to significant reductions in visfatin levels and improvements in metabolic parameters in men with NAFLD. Further studies are needed to evaluate the long-term implications of polypill consumption in managing NAFLD through targeting adipokines.<\/jats:p>","DOI":"10.1371\/journal.pone.0331121","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:28:56Z","timestamp":1759944536000},"page":"e0331121","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0159-5504","authenticated-orcid":true,"given":"Mahdieh","family":"Nazari-Robati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Dehesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8758-6686","authenticated-orcid":true,"given":"Beydolah","family":"Shahouzehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-0722","authenticated-orcid":true,"given":"Gholamreza","family":"Roshandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Poustchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9949-5773","authenticated-orcid":true,"given":"Solaleh","family":"Emamgholipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"9","key":"pone.0331121.ref001","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","article-title":"Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options","volume":"119","author":"C Grander","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"1","key":"pone.0331121.ref002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Z Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"pone.0331121.ref003","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00018-023-04966-7","article-title":"Liver endothelial cells in NAFLD and transition to NASH and HCC","volume":"80","author":"R-I Velliou","year":"2023","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"pone.0331121.ref004","first-page":"1237","article-title":"Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?","volume":"11","author":"V Francisco","year":"2022","journal-title":"Biology (Basel)"},{"issue":"2","key":"pone.0331121.ref005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI20785","article-title":"Adenovirus-mediated chronic \u201chyper-resistinemia\u201d leads to in vivo insulin resistance in normal rats","volume":"114","author":"H Satoh","year":"2004","journal-title":"J Clin Invest"},{"issue":"2","key":"pone.0331121.ref006","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.diabres.2011.12.014","article-title":"Visceral fat mass is always, but adipokines (adiponectin and resistin) are diversely associated with insulin resistance in Chinese type 2 diabetic and normoglycemic subjects","volume":"96","author":"J Bu","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"issue":"21","key":"pone.0331121.ref007","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.3748\/wjg.v22.i21.5096","article-title":"Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease","volume":"22","author":"R Jamali","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"1","key":"pone.0331121.ref008","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/ijms23010498","article-title":"Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future","volume":"23","author":"JPMD Santos","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"pone.0331121.ref009","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/biomedicines11092589","article-title":"The Interplay of Adipokines and Pancreatic Beta Cells in Metabolic Regulation and Diabetes","volume":"11","author":"J Kim","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"pone.0331121.ref010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/j.2040-4603.2017.tb00757.x","article-title":"Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase\/Visfatin","volume":"7","author":"F Carbone","year":"2017","journal-title":"Compr Physiol"},{"issue":"12","key":"pone.0331121.ref011","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.3390\/antiox12122046","article-title":"The Role of Adipokines and Myokines in the Pathogenesis of Different Obesity Phenotypes-New Perspectives","volume":"12","author":"M Pelczy\u0144ska","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"6","key":"pone.0331121.ref012","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/dmrr.1201","article-title":"Visfatin in overweight\/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review","volume":"27","author":"Y-H Chang","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"pone.0331121.ref013","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002630","article-title":"Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines","volume":"95","author":"R Jamali","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"pone.0331121.ref014","first-page":"28","article-title":"Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome","volume":"31","author":"Z Mousavi","year":"2017","journal-title":"Med J Islam Repub Iran"},{"issue":"8","key":"pone.0331121.ref015","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/MEG.0000000000001608","article-title":"Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter","volume":"32","author":"ZA Elkabany","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"pone.0331121.ref016","first-page":"16460","article-title":"Polypill in cardiovascular disease prevention: recent advances","volume":"133","author":"A Coca","year":"2023","journal-title":"Pol Arch Intern Med"},{"key":"pone.0331121.ref017","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2023.08.012","article-title":"A review of polypills for the prevention of atherosclerotic cardiovascular disease","volume":"266","author":"F Agnello","year":"2023","journal-title":"Am Heart J"},{"issue":"17","key":"pone.0331121.ref018","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.3390\/ijerph16173104","article-title":"Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications","volume":"16","author":"C Tana","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"21","key":"pone.0331121.ref019","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/eurheartj\/ehab919","article-title":"Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial","volume":"43","author":"S Merat","year":"2022","journal-title":"Eur Heart J"},{"issue":"8","key":"pone.0331121.ref020","doi-asserted-by":"crossref","first-page":"548","DOI":"10.34172\/aim.2020.58","article-title":"Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial","volume":"23","author":"F Malekzadeh","year":"2020","journal-title":"Arch Iran Med"},{"issue":"8","key":"pone.0331121.ref021","first-page":"515","article-title":"PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol","volume":"18","author":"S Merat","year":"2015","journal-title":"Arch Iran Med"},{"issue":"1","key":"pone.0331121.ref022","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40360-016-0102-9","article-title":"The polypill approach - An innovative strategy to improve cardiovascular health in Europe","volume":"18","author":"V Fuster","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"pone.0331121.ref023","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clinbiochem.2012.11.006","article-title":"Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease","volume":"46","author":"T Auguet","year":"2013","journal-title":"Clin Biochem"},{"issue":"5","key":"pone.0331121.ref024","first-page":"369","article-title":"Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and nonalcoholic steatohepatitis scores","volume":"103","author":"E Senate\u015f","year":"2012","journal-title":"Minerva Med"},{"issue":"6","key":"pone.0331121.ref025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1042\/CS20200895","article-title":"The complex role of adipokines in obesity, inflammation, and autoimmunity","volume":"135","author":"EB Taylor","year":"2021","journal-title":"Clin Sci (Lond)"},{"issue":"7","key":"pone.0331121.ref026","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.3390\/ijms25073694","article-title":"Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update","volume":"25","author":"JP De C\u00f3l","year":"2024","journal-title":"Int J Mol Sci"},{"key":"pone.0331121.ref027","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/bs.pmbts.2015.07.002","article-title":"Exercise and Regulation of Adipokine and Myokine Production","volume":"135","author":"SW G\u00f6rgens","year":"2015","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1","key":"pone.0331121.ref028","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2047-783X-18-12","article-title":"Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity","volume":"18","author":"EA Al-Suhaimi","year":"2013","journal-title":"Eur J Med Res"},{"issue":"9","key":"pone.0331121.ref029","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/ars.2021.0076","article-title":"Signal Transduction and Molecular Regulation in Fatty Liver Disease","volume":"35","author":"XC Dong","year":"2021","journal-title":"Antioxid Redox Signal"},{"issue":"8","key":"pone.0331121.ref030","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3390\/ijms18081740","article-title":"Epigenetic Regulation of Adipokines","volume":"18","author":"TX Pham","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"36","key":"pone.0331121.ref031","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.3748\/wjg.v22.i36.8078","article-title":"Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions","volume":"22","author":"MG Clemente","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"2","key":"pone.0331121.ref032","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3345\/cep.2023.00752","article-title":"Nonalcoholic fatty liver disease in children and adolescents","volume":"67","author":"HS Lee","year":"2024","journal-title":"Clin Exp Pediatr"},{"issue":"2","key":"pone.0331121.ref033","first-page":"169","article-title":"An evaluation of visfatin levels in obese subjects","volume":"61","author":"A Kami\u0144ska","year":"2010","journal-title":"Endokrynol Pol"},{"issue":"3","key":"pone.0331121.ref034","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/flgastro-2013-100403","article-title":"Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging","volume":"5","author":"JK Dyson","year":"2014","journal-title":"Frontline Gastroenterol"},{"issue":"5","key":"pone.0331121.ref035","first-page":"326","article-title":"Lipid Profiles and Serum Visfatin Concentrations in Patients with Type II Diabetes in Comparison with Healthy Controls","volume":"3","author":"H Hajianfar","year":"2012","journal-title":"Int J Prev Med"},{"key":"pone.0331121.ref036","article-title":"Association of Visfatin with Blood Glucose, Insulin Resistance and Body Mass Index in Patients with Type 2 Diabetes\/Pre-Diabetes","author":"H Karimi","year":"2022","journal-title":"JABS"},{"issue":"1","key":"pone.0331121.ref037","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7123\/01.EJIM.0000425961.54125.23","article-title":"Serum visfatin in type 2 diabetes mellitus","volume":"25","author":"SA Abd Rabo","year":"2013","journal-title":"Egypt J Intern Med"},{"issue":"3","key":"pone.0331121.ref038","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.4049\/jimmunol.178.3.1748","article-title":"Visfatin, an adipocytokine with proinflammatory and immunomodulating properties","volume":"178","author":"AR Moschen","year":"2007","journal-title":"J Immunol"},{"issue":"1","key":"pone.0331121.ref039","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3803\/EnM.2018.33.1.33","article-title":"Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease","volume":"33","author":"C Boutari","year":"2018","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"pone.0331121.ref040","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3892\/mmr.2014.2795","article-title":"Visfatin: an adipokine activator of rat hepatic stellate cells","volume":"11","author":"N-L Liang","year":"2015","journal-title":"Mol Med Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:29:02Z","timestamp":1759944542000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331121"}},"subtitle":[],"editor":[{"given":"Aleksandra","family":"Klisic","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0331121","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}